Erasca, Inc. (NASDAQ: ERAS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
18.14
-0.27-1.47%
Earnings
Down 1.5% — Earnings due 2026-08-11 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 11.80% | Shs Outstand | 347.13M | Perf Week | 1.43% |
| Market Cap | 6.39B | Forward P/E | - | EPS next Y | -0.55 | Insider Trans | -0.24% | Shs Float | 222.52M | Perf Month | -4.01% |
| Enterprise Value | 6.39B | PEG | 0.17 | EPS next Q | - | Inst Own | - | Short Float | 13.83% | Perf Quarter | 77.02% |
| Income | -315.70M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 4.44 | Perf Half Y | 54.97% |
| Sales | 0.00 | P/B | 14.24 | EPS next Y | 41.58% | ROA | -60.06% | Short Interest | 30.77M | Perf YTD | 394.89% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -77.01% | 52W High | 23.93 -24.18% | Perf Year | 1187.41% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -32.56% | 52W Low | 1.31 1284.21% | Perf 3Y | 600.00% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.04% 6.18% | Perf 5Y | -12.33% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -34.78% | Oper. Margin | 0.00% | ATR (14) | 1.15 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.52 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 52.58 | Recom | 2.18 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.52 | EPS Q/Q | -445.45% | SMA20 | -2.10% | Beta | 0.66 | Target Price | 22.83 |
| Payout | 0.00% | Debt/Eq | 0.12 | Sales Q/Q | - | SMA50 | 10.51% | Rel Volume | 0.42 | Prev Close | 18.41 |
| Employees | 103 | LT Debt/Eq | 0.13 | Earnings | Aug 11 | SMA200 | 62.89% | Avg Volume | 4.98M | Price | 18.14 |
| IPO Date | Jul 16, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -475.32% - | Net Debt/EBITDA | 0.00 | Volume | 2,093,405 | Change | -1.47% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-20-26 | Reiterated | Morgan Stanley | Equal Weight | $10 → $21 |
| Jul-14-26 | Reiterated | Jefferies | $6.00 → $24 | |
| Jul-14-26 | Reiterated | HSBC | $20 | |
| Jun-04-26 | Reiterated | Wolfe Research | $16 | |
| Jun-04-26 | Upgrade | B of A Securities | Underperform → Neutral | |
| May-12-26 | Reiterated | Mizuho | Outperform | $5.00 → $26 |
| Apr-27-26 | Reiterated | Stifel Nicolaus | $20 → $30 | |
| Mar-10-26 | Reiterated | Stifel Nicolaus | $10 → $20 | |
| Jan-27-26 | Reiterated | Guggenheim | Buy | $5.00 → $12 |
| Jan-26-26 | Reiterated | Morgan Stanley | Equal Weight | $4.00 → $10 |
Latest News
Today
Today08:30AM
03:48AM
03:39AM
Aug-09-26
Aug-09-2604:19PM
03:12PM
01:11PM
Aug-08-26
Aug-08-2604:51PM
01:11PM
Aug-07-26
Aug-07-2605:41PM
03:47PM
03:44PM
02:46PM
02:15PM
01:05PM
Company
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 3 | 0 | 4 | — | — | — | — | |
| Gross Profit | -3 | 0 | -4 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 39 | 42 | 38 | — | — | — | — | |
| Research and Development | 93 | 115 | 104 | — | — | — | — | |
| Other Operating Expense | -4 | 23 | -4 | — | — | — | — | |
| Operating Income | -131 | -180 | -142 | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 7 | 18 | 16 | — | — | — | — | |
| Net Income Before Taxes | -125 | -162 | -125 | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | |
| Consolidated Net Income | -125 | -162 | -125 | — | — | — | — | |
| Net Income From Continuing Operations | -125 | -162 | -125 | — | — | — | — | |
| Net Income | -125 | -162 | -125 | — | — | — | — | |
| EPS (Recurring) | -0.44 | -0.69 | -0.83 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.44 | -0.69 | -0.83 | — | — | — | — | |
| EPS (Diluted) | -0.44 | -0.69 | -0.83 | — | — | — | — | |
| EBITDA | -121 | -153 | -121 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 284 | 234 | 150 | — | — | — | — | |
| Market Capitalization | 1,056 | 587 | 320 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Garner Ebun | Chief Legal Officer | Apr 01 '26 | Option Exercise | 1.70 | 80,000 | 136,000 | 105,076 | Apr 03 |
| Garner Ebun | Chief Legal Officer | Apr 01 '26 | Sale | 16.40 | 80,000 | 1,312,000 | 25,076 | Apr 03 |
| Morris Shannon | Chief Medical Officer | Mar 04 '26 | Option Exercise | 1.70 | 20,000 | 34,000 | 20,000 | Mar 06 |
| Morris Shannon | Chief Medical Officer | Mar 04 '26 | Sale | 15.04 | 20,000 | 300,760 | 0 | Mar 06 |
| Morris Shannon | Chief Medical Officer | Mar 04 '25 | Option Exercise | 1.70 | 20,000 | 34,000 | 515,800 | Mar 06 |
| Garner Ebun | General Counsel & Corp. Sec. | Jan 07 '26 | Option Exercise | 1.70 | 120,000 | 204,000 | 145,076 | Jan 08 |
| Garner Ebun | General Counsel & Corp. Sec. | Jan 07 '26 | Sale | 5.59 | 120,000 | 670,812 | 25,076 | Jan 08 |
| Garner Ebun | General Counsel & Corp. Sec. | Jan 07 '25 | Option Exercise | 1.70 | 120,000 | 204,000 | 360,000 | Jan 08 |
| Casdin Alexander W. | Director | May 21 '24 | Buy | 2.27 | 80,000 | 181,920 | 573,974 | May 22 |
| Start Valerie Denise Harding | Director | Dec 06 '23 | Buy | 1.85 | 10,000 | 18,480 | 20,000 | Dec 08 |
| Lim Jonathan E | Chairman & CEO | Dec 06 '23 | Buy | 1.72 | 278,150 | 478,418 | 12,899,360 | Dec 06 |
| Lim Jonathan E | Chairman & CEO | Dec 05 '23 | Buy | 1.69 | 721,850 | 1,217,761 | 12,899,360 | Dec 06 |
| Casdin Alexander W. | Director | Dec 04 '23 | Buy | 1.66 | 30,000 | 49,785 | 493,974 | Dec 04 |
| Lim Jonathan E | Chairman & CEO | Oct 05 '23 | Buy | 2.03 | 1,000,000 | 2,026,000 | 19,456,216 | Oct 10 |
| Lim Jonathan E | Chairman & CEO | Jun 08 '23 | Buy | 2.75 | 100,000 | 275,000 | 18,396,216 | Jun 08 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.